CHPA meeting request
This article was originally published in The Rose Sheet
Executive Summary
Consumer Healthcare Products Association says meeting with FDA is planned in June to discuss the results of a pilot study on 20% benzocaine-containing oral care products. Trade group requested a meeting with the agency in a March 25 letter. Study was conducted after CHPA received a feedback letter from FDA in October 2002, responding to the association's proposed research program on benzocaine for temporary pain relief from toothache. Results address several key questions outlined by FDA, CHPA says, including "assessment of the subject's comprehension of the label directions for dosing, methodology to assess efficacy and the duration of treatment effect." CHPA also plans to discuss proposed protocol to evaluate 10% and 20% benzocaine and proposed OTC label...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.